ArticleJournal of orthopaedic translation2026
CMTM6 promotes synovial proliferation and macrophage polarization by preventing ubiquitination of TAK1 in rheumatoid arthritis.
Article in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Role of CMTM6 in disease pathogenesis and clinical translation potential (Review).Molecular medicine reports · 2026Review
- Integrating mechanistic research and emerging technologies to advance clinical translation in orthopaedics.Journal of orthopaedic translation · 2026Article
- Comment on "CMTM6 promotes synovial proliferation and macrophage polarization by preventing ubiquitination of TAK1 in rheumatoid arthritis".Journal of orthopaedic translation · 2026Article
- Advancing the continuum of orthopaedic translation: Mechanistic insight, regenerative innovation, and converging technologies.Journal of orthopaedic translation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation and bone destruction. Abnormal TNF/TNFR signaling leads to various dysregulations in Fibroblast-like synoviocytes (FLSs), including proliferation, migration, and cytokine production. CKLF like MARVEL transmembrane domain containing 6 (CMTM6) plays a crucial role in tumor progression and immune escape. This study aimed to research the function of CMTM6 in fibroblast-like synoviocytes (FLSs) of rheumatoid arthritis (RA). Materials and methods: The level of CMTM6 in serum and synovial fluid was detected by enzyme-linked immunosorbent assays (ELISA). Results: Increased levels of CMTM6 in the serum, synovial fluid and synovial tissues were observed in RA patients. Silencing Conclusions: CMTM6 participates in the proliferation, migration, and apoptosis of FLSs and exacerbates joint inflammation. Mechanistically, CMTM6 activates the NF-κB/MAPK signaling pathway by protecting TAK1 from ubiquitination degradation. The translational potential of this article: This study shows that CMTM6 mediates inflammatory signatures such as proliferation and migration of FLSs through TAK1. Targeting CMTM6 may become a potential therapeutic target for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.